Biotie Therapies Oyj : Change in the number of votes relating to Biotie
Therapies Corp.'s shares
Biotie Therapies Corp. Stock Exchange Release 4 March 2013 at
Change in the number of votes relating to Biotie Therapies Corp.'s shares
The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"),
Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie
Therapies Holding AG) has conveyed Biotie shares against consideration
pursuant to the option programs as follows:
February 2013 Total (5/2011- Options % of the total
2/2013) outstanding amount of
30,680 6,594,588 7,962,603 1.8%
The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and
consultants. In connection with the completion of the acquisition of Synosia,
the option plan was amended so that instead of shares in Synosia an aggregate
maximum of 14,912,155 shares in Biotie may be subscribed based on the plan.
Biotie issued these 14,912,155 shares to its current subsidiary Synosia in
connection with the acquisition to be further conveyed to the option holders
when they potentially exercise their option rights in accordance with the
terms and conditions of the option program.
The conveyed shares previously held by the Company's subsidiary have not
carried any voting rights. The parent company Biotie does not own any treasury
shares. The conveyance does not affect the number of registered shares.
After the conveyances the changes are as follows:
The increase of vote of A total amount of The number of the The total number
the Company voting rights: Company's share of registered
February 2013 held shares
by the Group
30,680 444,393,171 452,710,738
Turku, 4 March 2013
Biotie Therapies Corp.
President and CEO
For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
NASDAQ OMX Helsinki Ltd
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Biotie Therapies Oyj via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.